What the FDA labels say about taking them together
Glycine and remifentanil
Remifentanil's FDA label of December 15, 2025 names glycine in its contraindications section; the glycine labels PlainMeds reads (3) do not name remifentanil. The remifentanil label: “CONTRAINDICATIONS ULTIVA is contraindicated: For epidural or intrathecal administration due to the presence of glycine in the formulation.”
Check it at the source: the glycine FDA label on DailyMed (effective April 1, 2021, B. Braun Medical Inc.); the remifentanil FDA label on DailyMed (effective December 15, 2025, Mylan Institutional LLC).
What does the glycine label say about remifentanil?
Glycine's label (effective April 1, 2021) and its 2 other brand-application labels do not name remifentanil in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Glycine), B. Braun Medical Inc., effective April 1, 2021 (SPL set f4d83550-42de-44c7-b8d5-1d0debc6aec2), via openFDA; the full label on DailyMed
What does the remifentanil label say about glycine?
Remifentanil label, contraindicationsCONTRAINDICATIONS ULTIVA is contraindicated: For epidural or intrathecal administration due to the presence of glycine in the formulation [see Nonclinical Toxicology (13) ].
Source: FDA drug label (Ultiva), Mylan Institutional LLC, effective December 15, 2025 (SPL set 4dbcb8f9-1987-4b66-bd2f-d251fda0be10), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glycine | Remifentanil | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once